
Michelle R. Kuhne\textsuperscript{1}, Tanya Mulvey\textsuperscript{1}, Blake Belanger\textsuperscript{1} Sharline Chen\textsuperscript{1}, Chin Pan\textsuperscript{1}, Colin Chong\textsuperscript{1}, Fei Cao\textsuperscript{1}, Wafa Niekro\textsuperscript{2}, Tom Kempe\textsuperscript{2}, Karla A. Henning\textsuperscript{3}, Lewis J.Cohen\textsuperscript{4}, Alan J. Korman\textsuperscript{3}, and Pina M. Cardarelli\textsuperscript{1}

\textbf{Running Title:} Anti-CXCR4 in vitro and in vivo pre-clinical activity.

\textbf{Disclosure of Potential Conflicts of Interest:} The authors are employed by Bristol-Myers Squibb.

\textbf{Notes:}\n\textsuperscript{1} Bristol-Myers Squibb, BDC, Department of Cell Biology and Physiology, Sunnyvale, CA; \textsuperscript{2} BDC, Department of Hybridoma Milpitas, CA; \textsuperscript{3} BDC, Department of Discovery Research, Milpitas, CA; \textsuperscript{4} Bristol-Myers Squibb, Discovery Medicine and Clinical Pharmacology, Lawrenceville, NJ.

Corresponding author: pina.cardarelli@bms.com. All authors are employed at BMS. Word count: 5,000. Total figures and tables: 6.

\textbf{Keywords:} CXCR4, antibody, apoptosis, AML, multiple myeloma
Abstract

**Purpose:** CXCR4 has been identified as a prognostic marker for acute myeloid leukemia (AML) and other malignancies. We describe the development and characterization of a fully human antibody to CXCR4 and its application for therapy of AML, non-Hodgkin’s lymphoma (NHL), chronic lymphoid leukemia (CLL), and multiple myeloma (MM).

**Experimental Design:** Human transgenic mice were immunized with CXCR4 expressing cells and antibodies reactive with CXCR4 were analyzed for apoptosis induction and ability to interfere with CXCL12-induced migration and calcium-flux. In vivo efficacy was determined in multiple AML, NHL, and MM xenograft tumors in SCID mice.

**Results:** BMS-936564/MDX-1338 is a fully human IgG4 monoclonal antibody that specifically recognizes human CXCR4. In vitro studies demonstrate that MDX-1338 binds to CXCR4-expressing cells with low nanomolar affinity, blocks CXCL12 binding to CXCR4 expressing cells and inhibits CXCL12 induced migration and calcium flux with low nanomolar EC50 values. When given as monotherapy, MDX-1338 exhibits anti-tumor activity in established tumors including AML, NHL, and MM xenograft models. Additionally, we show that MDX-1338-induced apoptosis on a panel of cell lines and propose that antibody induced apoptosis is one of the mechanisms of tumor growth inhibition.
Conclusions: BMS-936564/MDX-1338 is a potent CXCR4 antagonist which is efficacious as monotherapy in tumor bearing mice and is currently in Phase I for the treatment of relapsed/refractory AML, NHL, CLL, and MM.

Translational Relevance: Expression of CXCR4 has been identified as a prognostic indicator for acute myeloid leukemia (AML) and other malignancies, in which greater expression of CXCR4 correlates with disease severity. CXCR4 plays an important role in both homing and retention of leukemic or stem cells in the bone marrow and an antagonist of CXCR4 mobilizes these cells into the bloodstream. In addition to mobilization, a direct apoptotic effect of the antibody was discovered suggesting that direct killing may be a mechanism for tumor growth inhibition. These features, together with the fact that an antibody has a longer half life, may offer advantages over a small molecule. Consequently, clinical trials in relapsed/refractory AML, NHL, CLL, and MM are currently ongoing.

INTRODUCTION

CXCR4, also known as CD184, is a 7 transmembrane spanning protein consisting of an extra-cellular N-terminal tail and three extra-cellular loops. The intracellular carboxy terminus of CXCR4 is coupled to a heterotrimeric G-protein consisting of β and γ subunits and a pertussis toxin-sensitive Gi α subunit. To date, only one ligand for CXCR4, CXCL12, also known as SDF-1 has been identified. CXCL12 binding to CXCR4 stimulates activation of phospholipase C and subsequently results in an elevation of cytosolic free calcium. Ligation of CXCR4 ultimately leads to induction of chemotaxis and migration.
found in various tissues with predominant expression on hematopoietic lineage cells including B and T cells, monocytes, macrophages, NK, and dendritic cells, as well as CD34+ bone marrow progenitor cells.6 Low levels of CXCR4 are also expressed on endothelial and epithelial cells, astrocytes, and neurons.7,8 CXCL12 has been shown to induce endothelial cell migration and proliferation and together with VEGF were shown to enhance neoangiogenesis.9

Over expression of CXCR4 has been found in 75% of cancers including leukemias, lymphomas, pancreatic, breast, ovarian, lung, prostate and colorectal tumors. Additionally, this pathway is implicated in stimulating the metastatic process in multiple neoplasms.10 In clinical studies, CXCR4 has been associated with increased propensity for metastasis and decreased survival and was identified as a prognostic indicator for AML, breast, colorectal, non small cell lung, ovarian and pancreatic carcinoma in which greater expression of CXCR4 correlates with disease severity.11,12,13,14,15,16

Bone marrow stromal cells secrete CXCL12 and the interaction with CXCR4 is essential for homing and maintaining hematopoietic stem cells within the bone marrow microenvironment.17 Leukemic cells express high levels of CXCR4, and the pathway plays a critical role in leukemic cell migration into the bone marrow which in turn, supports their growth and survival. CXCR4 is essential for metastatic spread to organs such as bone marrow where CXCL12 is expressed. Collectively, CXCR4 plays an important role in both homing and retention of hematopoietic stem cells in the bone marrow and an antagonist of CXCR4 mobilizes stem cells into the bloodstream, as demonstrated with the small
Anti-CXCR4 in vitro and in vivo pre-clinical activity

molecule CXCR4 antagonist, plerixofor (Mozobil) which was approved by the FDA for use in combination with granulocyte-colony stimulating factor for autologous transplants in NHL and MM patients.\textsuperscript{18}

In AML, CXCR4 is highly expressed on the CD34\textsuperscript{+} fraction of bone marrow cells. Lower levels of CXCR4 on AML cells correlate with a better prognosis resulting in a longer relapse free and overall survival. The lower CXCR4 receptor expression attenuates migration of primary AML cells toward CXCL12 expressed in the chemo-protected environment of the bone marrow.\textsuperscript{19} In addition to AML, serum levels of CXCL12 are elevated in patients with multiple myeloma and CXCR4 expression increases in extramedullary plasmacytoma, a manifestation of an advanced stage of multiple myeloma. Furthermore, blockade of the CXCL12/CXCR4 axis attenuates tumor growth in MM tumor models.\textsuperscript{20}

In this report we describe the generation of a fully human monoclonal antibody specific for human CXCR4. MDX-1338 has low nM affinity for CXCR4 and effectively blocks CXCL12 binding to CXCR4 thereby inhibiting calcium flux and migration. MDX-1338 induces apoptosis on a panel of tumor cell lines and significantly reduces in vivo tumor growth in several xenograft models. These data support the development of MDX-1338 for treatment of patients with hematologic malignancies.

**MATERIALS & METHODS**

**Materials**
Anti-CXCR4 in vitro and in vivo pre-clinical activity

Isotype Control antibody IgG₄ containing the S228P hinge mutation to reduce half-antibody formation was produced at Medarex (Acquired by BMS and currently renamed BDC), Sunnyvale, CA; The following reagents were purchased: CXCL12 from Peprotech (Rocky Hill, NJ); ¹²⁵I- CXCL12 from PerkinElmer (Waltham, MA); Calcium dye (FLIPR Calcium 4 kit) from Molecular Devices (Sunnyvale, CA); Bis (acetoxyethyl) 2,2′,6′,2″-terpyridine-6,6″-dicarboxylate (BADTA) chemiluminescent migration reagent and DELFIA Europium solution from PerkinElmer (Waltham, MA); Annexin V Binding Buffer 10x concentrate, 7-Amino-Actinomycin D (7-AAD), and Annexin V-APC from BD Biosciences, (San Jose, CA); Phycoerythrin-conjugated goat anti-human antibody from Jackson ImmunoResearch, West Grove, PA (Cat. 109-116-098).

Acute myelogenous leukemia (AML) peripheral blood mononuclear cells from AllCells LLC. (Emeryville, CA) and Cureline Inc. (Burlingame, CA).

Cells

lymphoma (TIB-161), NK92 human NK cell non-Hodgkin’s lymphoma (CRL-2407) cell lines were purchased from ATCC, Manassas, VA.

NOMO-1 human acute myeloid leukemia (ACC 542), MOLP-8 MM (ACC 569), SU-DHL6 human B cell non-Hodgkin’s lymphoma (ACC 572), L540 human Hodgkin’s lymphoma (ACC 72), KG-1 human AML (ACC 14), MOLP-8 human MM (ACC 569), OPM-2 human MM (ACC 50), L-363 human plasma cell leukemia (ACC 49) cell lines were purchased from DSMZ, Braunschweig, Germany.

R1610 hamster fibroblasts (CRL-1657) purchased from ATCC were transfected with human CXCR4 and kept under selection using G418 at 500 µg/mL. JJN-3 cells (ACC 541) purchased from DSMZ were selected at BMS for resistance to bortezomib. NKL human NK cell large granulocyte leukemia cell line licensed from Dana-Farber Cancer Institute; KHYG-1 human NK cell leukemia cell line (JCRB0156) was purchased from the Health Science Research Resources Bank, Japan Health Sciences Foundation.

**FACS Instrument and Software**

A FACSArray or FACSCalibur (BD Biosciences, San Jose, CA) instrument and FlowJo software v8 (TreeStar Inc, Ashland, OR) were used to collect and analyze data.

**Antibody generation**

Mice from Medarex KM® transgenic mouse colonies (Milpitas, CA) were immunized with human CXCR4 transfected R1610 cells or recombinant
CXCL12. Spleen lysates were pooled and processed as described previously. Using proprietary phage display procedures, Biosite generated antibody fragments (Fab library). Phage which bound to CXCR4 were selected on CXCR4 magnetic proteoliposomes (MPLs) which were prepared from HEK293E cells expressing CXCR4. Phage binding to CXCL12 were selected using biotinylated-CXCL12. Selected antigen reactive Fab were converted to full length IgG (S228P) and re-expressed in CHO cells.

**Functional characterization of CXCL12 and CXCR4**

Serial dilutions of MDX-1338, anti-CXCL12 and control antibody were tested for blockade of 125I-CXCL12 binding to CXCR4+ CEM cells. Competition of 125I-CXCL12 binding to CXCR4 on CEM cells was demonstrated using a fixed concentration of 125I-CXCL12 (100 pM) and a titration of MDX-1338 from 5 pM to 300 nM. An isotype antibody was used as a negative control and unlabeled CXCL12 was used as a positive control. Plates were incubated at room temperature for 1 hour, the filters were washed, removed and counts per minute (CPM) were read by a PerkinElmer Wizard gamma counter (Waltham, MA). For all in vitro studies, the data was graphed and analyzed with GraphPad Prism® software (San Diego, CA), using nonlinear regression and sigmoidal dose-response curves.

Cells were loaded with FLIPR Calcium 4 dye (Molecular Devices, Sunnyvale CA). A fixed concentration of CXCL12 was used to stimulate calcium flux. A titration of MDX-1338 or anti-CXCL12 from 50 pM to 100 nM was used to inhibit the response. A maximal calcium response was set with CXCL12 minus
Anti-CXCR4 in vitro and in vivo pre-clinical activity

antibodies. A baseline response was established with buffer stimulation of cells without CXCL12. Calcium fluxes were read on the Flexstation (Molecular Devices, Sunnyvale, CA).

Cells were loaded with BATDA. A fixed concentration of CXCL12 was used to stimulate migration of cells through a filter containing 5 µm pores on Migration Plates from Neuro Probe (Gaithersburg, MD; Cat. ChemoTx 106-5). A titration of MDX-1338 or anti-CXCL12 from 20 pM to 300 nM was added to the cells. CXCL12 without antibody was used to establish maximal migration. Migration toward media alone without CXCL12 was used to measure background migration. Following 2 hour incubation at 37 °C, migrated cells were detected by addition of Europium solution to the lysed cells and detected by time resolved fluorescence on the Fusion (Perkin Elmer).

For proliferation, cells were suspended at 1 x 10⁵ cells/mL in growth media and incubated with antibodies and cultured for 72 hours at 37 °C. Cell-Titer-Glo (Promega) was added to wells, mixed and incubated at room temperature for 10 minutes. Plate was read on GloMax Luminometer (Promega).

For apoptosis assays, cells (5 x 10⁵ cells/mL) were incubated with 10 nM - 330 nM MDX-1338 or isotype control at 37 °C for 24 hours. For a subset of cells (see Table 1), a cross linking antibody (Goat anti-human IgG Fc specific polyclonal Ab) was added at six-fold excess. For all cell types, camptothecin (CPT) was added at 10 µM for 24 hours at 37º C as a positive control for apoptosis induction. Cells were then resuspended in Annexin V binding buffer (10 mM HEPES at pH 7.4, 140 mM NaCl, 2.5 mM CaCl₂) and stained with
Annexin V-APC and 7-Aminoactinomycin D (7-AAD) or propidium iodide (PI). Cells were then washed, resuspended in Annexin V binding buffer, and analyzed with a FACSArray system (BD Biosciences, San Jose, CA) and FlowJo software (Treestar, Inc., San Carlos, CA).

**Tumor Models**

SCID mice were subcutaneously implanted with 10 million Ramos cells, or HL-60 cells, or 7.5 million of Nomo-1 cells, or 2.5 million MOLP-8 cells, or 5 million JJN-3R cells in 0.1 mL phosphate-buffered saline (PBS) and 0.1 mL Matrigel, using a 1-cm³ syringe and a 25-gauge half-inch needle. One day prior to dosing, mice were randomized into groups of 8-10 mice each according to tumor volume (L×W×H/2). Post implantation, mice were dosed with MDX-1338 at 3-30 mg/kg IP; human IgG₄ isotype (15 or 30 mg/kg IP); bortezomib® (1.0 or 0.8 mg/kg IV); and vehicle control was dosed at 0.3 mL IP. Mice were dosed every three to four days for five doses. Tumors and body weights were measured twice weekly. Tumors were measured in three dimensions with a Fowler Electronic Digital Caliper (Model 62379-531; Fred V. Fowler Co., Newton, MA), and data was electronically recorded using StudyDirector software from Studylog Systems, Inc. (South San Francisco, CA). Animals were checked daily for postural, grooming, and respiratory changes, as well as lethargy. Mice were euthanized when the tumors reached the 2000 mm³ endpoint or appeared ulcerated. All antibody doses were well tolerated and no body weight losses were observed.
RESULTS

CXCR4 is expressed on multiple hematopoietic cell lines and variably expressed in AML patients.

A number of CXCR4 positive human cell lines were evaluated for MDX-1338 binding using flow cytometry. Dose-dependent binding was seen for the cell lines R1610-huCXCR4, Ramos, CEM, Nomo-1, HL-60, MOLP8 and JJN-3R (Figure 1). No binding to the R1610 parental cells was detected. Based upon geometric mean fluorescent intensity (GMFI), CXCR4 levels were highest on R1610-huCXCR4 and Ramos cells followed by CEM (Figure 1B), Nomo-1 and HL60 (Figure 1A). The multiple myeloma cell lines MOLP-8 and JJN-3R expressed the lowest number of receptors (Figure 1C). The EC$_{50}$ values for binding were 2.3 nM, 4.2 nM, 10.3 nM, 40 nM, 5.3 nM, 6.5 nM and 2.0 nM for R1610-huCXCR4, Ramos, CEM, Nomo-1, HL-60 MOLP-8 and JJN-3R cells, respectively. In addition, MDX-1338 bound to healthy donor PBMCs (data not shown) as well as 7/8 PBMCs samples collected from AML patients with variable GMFI (Figure 1D).

Ligand Blockade

Saturation binding studies were conducted using radiolabeled CXCL12 and CXCR4$^{hi}$ CEM cells. The K$_D$ of $^{125}$I-CXCL12 binding to CEM cells was determined to be 4.3 nM (data not shown) which is similar to the reported K$_D$ of CXCL12 for CXCR4 ranging from 3.0 to 5.4 nM.$^{24}$ Using a suboptimal fixed concentration of $^{125}$I-CXCL12 (100 pM), MDX-1338 was titrated and dose-dependent inhibition of $^{125}$I-CXCL12 binding with an EC$_{50}$ value of
approximately 2 nM was observed (Figure 2A). Interestingly, the anti-CXCL12 antibody was more potent and induced a dose-dependent inhibition of $^{125}$I-CXCL12 binding to CEM cells with an EC$_{50}$ value of approximately 90 pM (Figure 2B).

**Blockade of CXCL12-Induced Calcium Flux**

Ramos and CEM cells were used to test the capacity for MDX-1338 and anti-CXCL12 to inhibit calcium flux. CXCL12 induces a dose dependent rise in intracellular calcium with peak calcium flux reached at 50 nM and 5 nM with Ramos and CEM cells, respectively. Using the optimal concentration of CXCL12 to stimulate calcium flux, a titration of MDX-1338 or anti-CXCL12 was used to inhibit the response (Figure 2 C-D). Both MDX-1338 and anti-CXCL12 blocked CXCL12-induced calcium flux in a dose dependent manner with an EC$_{50}$ of approximately 10 nM and 8 nM in Ramos and CEM, respectively (Figure 2C and 2D). Anti-CXCL12 blocked with an EC$_{50}$ of approximately 35 nM (Ramos) and 2 nM (CEM) cells (Figure 2C and 2D).

**Blockade of CXCL12-Induced Migration**

The optimal concentration of CXCL12 for inducing Ramos migration was established to be 10 ng/mL (1.25 nM) while CEM cells were more sensitive to CXCL12 and exhibited maximal migration at 0.05 nM CXCL12. MDX-1338 was shown to block CXCL12-induced migration with an approximate EC$_{50}$ value of 1 nM in Ramos cells and 4 nM in CEM cells (Figure 2E and 2F). Anti-CXCL12 inhibited CXCL12-induced migration with an approximate EC50 value of 0.9 nM (Ramos) and 0.13 nM (CEM) cells (Figure 2E and 2F).
Comparison of anti-CXCR4 and anti-CXCL12 antibodies in vivo

To test the in vivo activity of MDX-1338 and anti-CXCL12, SCID mice bearing established Ramos tumor xenografts were treated with 15 mg/kg of antibody. Dose response studies had previously found 15 mg/kg to be an effective dose of rituximab (data not shown). MDX-1338 and positive control, rituximab, inhibited tumor growth when compared with vehicle and isotype controls. Treatment with MDX-1338 resulted in a median growth inhibition of 99% on Day 21 and the inhibition was maintained for 60 days (Figure 3A). In contrast, anti-CXCL12 did not inhibit tumor growth and performed similarly to the isotype control antibody.

In Vitro Induction of Apoptosis

Because we observed robust in vivo activity, studies were undertaken to understand the mechanism of action of MDX-1338. A maximum of ~50% inhibition of Ramos cell proliferation was seen with 40 nM MDX-1338 treatment (Figure 4A) compared to isotype control. By comparison, AMD3100, a small molecule CXCR4 antagonist did not inhibit proliferation. A recently described peptide antagonist, BKT140, did inhibit proliferation however at much higher concentrations (100 μM).

Antibody-induced apoptosis was investigated using Ramos cells and MDX-1338 for 24 hours. For comparison, the small molecule CXCR4-antagonist, AMD3100 was investigated using 6 μM corresponding to a concentration which inhibited CXCL12-induced calcium flux and migration.
MDX-1338 induced an increase in Annexin V (31.2%) and in Annexin V/PI double positive staining (27.3%) compared with cells that were either untreated (1.7% and 4.1%), incubated with isotype control antibody (0.5% and 2.8%), or treated with AMD3100 (2.0% and 2.7%) (Figure 4B and 4C).

To verify the specificity of the response to MDX-1338, parental R1610 which do not bind MDX-1338 (data not shown) and R1610 transfected with human CXCR4 that do bind to MDX-1338 (Figure 1) were used to measure apoptosis. The transfected cells R1610-hCXCR4 exhibited an increased level of Annexin V staining and Annexin V/PI in response to incubation with MDX-1338 (24.3% and 11.4%) while an isotype control antibody (2.5% and 0.9%) or when untreated (2.6% and 0.9%) had minimal effects. The parental R1610 cells did not exhibit apoptosis following MDX-1338 treatment (Figure 5) suggesting specificity for hCXCR4. Subsequent to these findings MDX-1338 was shown to induce apoptosis on several CXCR4 positive cell lines as well as normal PBMC (Table 1).

**MDX-1338 inhibits tumor growth of AML models.**

To assess the antibody’s efficacy in AML we used two cytarabine resistant mouse xenograft models, HL-60 and Nomo-1. The CXCR4 expression in each cell line was confirmed by FACS staining (Figure 1A). SCID mice containing established HL60 tumors were treated with MDX-1338 and on Day 27, the median tumor growth inhibition was 88% and 83% when compared to isotype and vehicle groups, respectively (Figure 3B).
Anti-CXCR4 in vitro and in vivo pre-clinical activity

In the Nomo-1 model, the mice were dosed with MDX-1338 or cytarabine and monitored for 57 days. On day 34, the median tumor growth inhibition of MDX-1338 treated mice was significantly delayed by 88% compared to isotype or vehicle control (Figure 3C). As expected, Cytarabine did not inhibit tumor growth.

**MDX-1338 inhibits tumor growth of MM models.**

CXCR4+ myeloma cells, MOLP8 and JJN-3R, were tested for sensitivity to MDX-1338 in SCID xenograft tumor models. MOLP8 cells were implanted into SCID mice and the mice were treated with, 10 mg/kg/dose of MDX-1338 ±50 mg/kg lenalidomide or ±0.8 mg/kg bortezomib (Figure 3D). MDX-1338 significantly delayed mean tumor growth by 66% and 56% when compared to isotype control on Day 25 (last day when all mice in each cohort remained in the study). MOLP8 tumors were relatively resistant to lenalidomide and bortezomib and the efficacy of MDX-1338 was not improved when combined with either drug. At the end of study on day 42, 5 out of 8 mice remained in the MDX-1338 group while no mice remained in the isotype treated group. The bortezomib resistant, JJN3R cells were implanted into SCID mice and mice were dosed when the tumors were established. Median tumor growth over time is shown in Figure 3E. Neither lenalidomide nor bortezomib alone inhibited tumor growth while median tumor growth inhibition was 100% for mice treated with MDX-1338 on day 25 compared to mice treated with isotype. At the end of study, 4 out of 7 mice were tumor free in the MDX-1338 30 mg/kg group.

**Discussion**
Anti-CXCR4 in vitro and in vivo pre-clinical activity

A novel, first in class therapeutic monoclonal antibody directed to CXCR4 has been developed. In addition to blocking CXCL12-induced calcium flux and migration, we describe antibody dependent induction of apoptosis as another mechanism of action. Antibody-induced apoptosis resulted in robust in vivo efficacy across multiple hematopoietic tumor xenograft models. Because CXCR4 plays a role in multiple fundamental aspects of cancer including proliferation, migration/invasion and angiogenesis, an antagonist has potentially multiple means to intervene in malignancies where CXCR4 is expressed. To begin to dissect the pathway, we developed fully human monoclonal antibodies to both CXCR4 and CXCL12. Both the anti-CXCR4 and anti-CXCL12 antibodies inhibit ligand binding to CXCR4 resulting in inhibition of ligand-induced cellular responses such as calcium flux and migration (Figure 2). In addition to these functions, the CXCR4/CXCL12 axis has been implicated in promoting angiogenesis.\textsuperscript{9,25} Both anti-CXCR4 and anti-CXCL12 antibodies also inhibited endothelial tube formation (data not shown), an in vitro demonstration of angiogenesis.

To test our theory that disruption of CXCR4/CXCL12 interactions will result in attenuation of tumor growth, we tested the efficacy of the antibodies in an in vivo xenograft model. Ramos cells were engrafted into SCID mice and Rituximab was used as a positive control. To our surprise, anti-CXCL12 antibody did not control tumor growth and appeared indistinguishable from vehicle and isotype control. In contrast, anti-CXCR4 antibody demonstrated nearly complete tumor growth control with similar activity as Rituximab (Figure 3). Because in vitro blockade of chemotaxis was similar between the two antibodies, it is
unlikely that anti-tumor control is dependent on blockade of the CXCL12/CXCR4 axis. A direct effect of MDX-1338 was tested in a Ramos cell proliferation assay. CXCL12 has been implicated as an autocrine factor promoting cell growth and in a separate study CXCL12 siRNA inhibited BR5-1 growth.\textsuperscript{26, 27}. Though the inhibition of growth was partial in our studies, we observed a dose-dependent inhibition of proliferation with anti-CXCR4 while AMD3100, and anti-CXCL12 antibody had no effect. Recently, a 14-residue polypeptide reported to be a specific CXCR4 antagonist (BKT140) was shown to inhibit proliferation of multiple myeloma cells.\textsuperscript{28} It has been suggested that AMD3100 is a weak partial agonist while BKT140 acts as an inverse agonist.\textsuperscript{29}

Multiple agents are being developed or are approved for CXCL12/CXCR4 targeted therapy including small molecule inhibitors, AMD3100 (Plerixafor, Mozobil, developed by Genzyme), BKT140 (Biokine Therapeutics)\textsuperscript{28}, a cyclic peptide CXCR4 antagonist (Eli Lilly)\textsuperscript{30} and CTCE-9908 developed by Chemokine Therapeutics\textsuperscript{31,32}. In addition, an anti-CXCR4 antibody developed by Eli-Lilly has been discontinued and an antibody developed by Pierre Fabre Medicament\textsuperscript{33} is in pre-clinical development. Finally a first in man study of ALX-0651, a nanobody inhibiting CXCR4 was initiated in healthy volunteers by Ablynx.\textsuperscript{34} How these various therapies will be differentiated needs to be determined. We have compared the activity of AMD3100 with MDX-1338 and there was no apoptosis observed with AMD3100 suggesting the antibody binding to CXCR4 drives a signal to induce apoptosis and is not simply antagonizing ligand binding. Our current data supports that MDX-1338 activates the intrinsic-
apoptotic pathway. The specific signaling pathways that CXCR4 engages upon antibody binding is currently being investigated.

The observation of CXCR4-mediated apoptosis by binding of HIV-1 envelope glycoprotein-gp120 to CXCR4 has been reported.\textsuperscript{35} Investigation revealed that antibodies cross-linked to CXCR4 could mimic the cell death observed with gp120-induction.\textsuperscript{36} Those authors suggested the use of anti-chemokine receptor antibodies to prevent HIV-1 infection might result in efficient and rapid destruction of the receptor expressing T-cells. We measured anti-CXCR4-induced apoptosis in over 20 different CXCR4-expressing cell lines (Table 1) confirming that this mechanism is not restricted to one cell type. Though MDX-1338 binds to healthy peripheral blood leukocytes, preliminary data from our AML trial has shown that the drug is well tolerated. To date, over 40 patients have been dosed up to 10mg/kg and we have not seen any adverse events associated with the antibody.

In vivo published data support that antagonists of CXCR4 are efficacious in AML and MM tumor models by enhancing the sensitivity of the tumors cells to chemotherapy.\textsuperscript{37,38} In contrast, in the studies presented here, we show that a statistically significant tumor growth inhibition was achieved when MDX-1338 was administered as monotherapy in AML and MM models.
Since MDX-1338 is an IgG4 antibody, the in vivo efficacy cannot be explained by ADCC or CDC. However, it is possible that the antibody, once bound to CXCR4-expressing cells, engages FcγR1 receptors expressed on antigen presenting cells leading to phagocytosis. The cell lines, in which MDX-1338 efficacy was observed in vivo, required a secondary anti-Fc antibody to MDX-1338 to induce apoptosis in vitro. This may be a consequence of lower expression of CXCR4 on those particular cell lines. If the mechanism of apoptosis initiation is dependent upon bringing CXCR4 molecules into close proximity, and the density of CXCR4 on the cell surface is low relative to the binding distance spanned by the anti-CXCR4 antibody, then a secondary high-affinity anti-Fc antibody may be required to bridge that gap, bringing the receptors together to drive an apoptotic signal. In vivo, this may be accomplished through FcγR1 receptors.

In conclusion, we propose a novel mechanism of action for an anti-CXCR4 antibody in addition to its role in cellular mobilization, and propose that MDX-1338 may be an effective therapy for AML, MM and other hematologic and possibly solid tumor malignancies.
Anti-CXCR4 in vitro and in vivo pre-clinical activity


Anti-CXCR4 in vitro and in vivo pre-clinical activity


30. United States patent application 20120052097, Oliver S. Fetzer, Jungyeon Hwang, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson, Therapeutic peptide-polymer conjugates, particles, compositions, and related methods publication date 2012-03-01.


34. Clinical Trials.gov-NCT01374503


Anti-CXCR4 in vitro and in vivo pre-clinical activity


Table Legends

**Table 1: Apoptosis Data on a Panel of Cell Lines.** Cells were incubated with 10 nM - 330 nM MDX-1338 or isotype control at 37°C for 24 hours. For a subset of cells, a cross linking antibody (Goat anti-human IgG Fc specific polyclonal Ab) was added at 6-fold excess. Cells were then resuspended in Annexin V binding buffer and stained with Annexin V-APC and 7-Aminoactinomycin D (7-AAD) or propidium iodide (PI). Cells were then washed, resuspended in Annexin V binding buffer, and analyzed with a FACSArray system and FlowJo software.

Figure Legends

**Figure 1. Flow Cytometric Analysis of MDX-1338 Binding.**

MDX-1338 binds to AML cell lines Nomo-1 and HL-60 (**A**), CXCR4 Transfected R1610 Cells, CEM, and Ramos (**B**), MM cell lines, JJN-3R, and MOLP8 (**C**) and primary AML patient blood cells (**D**). Cells were prepared for flow cytometry (FACS) staining by suspending cells with the indicated concentrations of naked MDX-1338 or biotinylated MDX-1338 before incubating the mixture of antibody and cells with goat anti-human FCγ-PE or PE-conjugated streptavidin. Cells were analyzed by FACS by gating on the live cell population identified by FSC and SSC.
Anti-CXCR4 in vitro and in vivo pre-clinical activity

**Figure 2: MDX-1338 blocks CXCL12 binding and cell signaling effects.**

Ligand binding (A and B) assays were conducted by incubating 100pM $^{125}$I-CXCL12 with Ramos cells in the presence of increasing concentration of MDX-1338 (■) or isotype control antibody (▲). Unlabeled CXCL12 was added at 1000 fold molar excess (100nM) to establish non-specific binding (NSB). $^{125}$I-CXCL12 without antibody or unlabeled competitor was added to establish total achievable binding (Total). Calcium Flux assays were conducted by incubating either Ramos cells (C) or CEM cells (D) with Calcium 4 ± MDX-1338 or an isotype control. Dye-loaded cells were incubated at room temperature with 50 nM and 5 nM CXCL12, with Ramos cells and CEM, respectively. The area under the curve of fluorescence between 20 to 200 seconds was quantitated and an EC50 was calculated. Migration assays with Ramos (E) and CEM (F) cells was carried out in the presence of 1.25 nM and 0.05 nM CXCL12 respectively. The number of labeled cells, which had migrated into the lower compartment, was measured on a Fusion (PerkinElmer) plate reader. Each point represents n = 3.
Figure 3. A blocking CXCR4 antibody inhibits tumor growth in vivo while a blocking CXCL12 antibody does not inhibit tumor growth.

A. Ramos cells were implanted subcutaneously and when a mean and median tumor size of 80 mm$^3$ was reached, the mice were randomized (n = 8). On Days 0 and 7 each animal was injected intraperitoneally (i.p.) with ~200 μL of MDX-1338 (15 mg/kg/dose), Anti-CXCL12 (15 mg/kg/dose), human IgG4 isotype control (15 mg/kg/dose), Rituximab (15 mg/kg/dose) or PBS (vehicle control). Tumors were measured in 3 dimensions (LxWxH/2). When the tumor was at least 2000 mm$^3$ or appeared ulcerated, animals were euthanized. 

B. HL-60 cells were implanted subcutaneously into SCID mice. When the tumor volume reached approximately 136 mm$^3$, the mice were randomized (n = 10) and dosed on Days 0, 3, 7, 10 and 14 and monitored for 41 days. 

C. Nomo-1 cells were implanted s.c. into SCID mice. When the tumor volume reached approximately 84 mm$^3$, the mice were randomized (n = 9) and dosed on days 0, 3, 7, 10 and 14. 

D. MOLP8 cells were implanted into SCID mice. When the tumor volume reached approximately 100 mm$^3$, the mice were randomized (n = 8) and dosed on days 0, 3, 7, 10 and 14 with MDX-1338 alone or with 50 mg/kg lenalidomide or with 0.8 mg/kg bortezomib. 

E. JJN3R cells were implanted and when the tumor volume reached approximately 100 mm$^3$, the mice were randomized (n = 8) and dosed with MDX-1338 or 50mg/kg lenalidomide or 0.8 mg/kg bortezomib. Dosing occurred on days 0, 4, 7, 11 and 14 and monitored for 25 days.
Figure 4. **MDX-1338 inhibits proliferation and induces apoptosis.**

Ramos cells were cultured with MDX-1338 or isotype control antibody for a total of 72 hours. $^3$H Thymidine incorporation was measured following 24 hours of incubation (A). In panels B and C, apoptosis assays were carried by incubating Ramos cells for 24 hours at 37 °C with 10 μg/mL MDX-1338 or isotype control. Cells were stained with Annexin V – FITC and PI. The percent of cells positive for Annexin V only or both Annexin V and PI double positive was determined.

Figure 5. **Induction of Apoptosis by MDX-1338 is CXCR4 specific.**

MDX-1338 or isotype control were added to R1610 parental cells (B) and CXCR4 transfected cells (A) for 24 hours at 37°C then stained with Annexin V – FITC and propidium iodide (PI). The percent of cells that are positive for Annexin V only or both Annexin V and PI double positive was determined.
Figure 1 A

Figure 1
A.

AML Cell Lines

GMFI

Isotype Control

Antibody Concentration (nM)

0.1 1 10 100 1000

0 10000 20000 30000 40000 50000 60000

Nomo-1
HL-60
Figure 1 B

Transfectants, Leukemia, Lymphoma Cell Lines

Antibody Concentration (nM)

GMFI

R1610-CXCR4

CEM

Ramos
Figure 1 C

c.

MM Cell Lines

- MOLP8
- JJN-3R

GMFI

Isotype Control

Antibody Concentration (nM)

0.01 0.1 1 10 100 1000
Figure 1D

D.

AML Patients PBMC

AML Subtype
Figure 2 A

A. Anti-CXCR4 Blockade of Binding

![Graph showing CPM vs Antibody Concentration (nM) for CEM Cells. The graph compares Anti-CXCR4 (MDX-1338) and Isotype Control. The y-axis represents CPM ranging from 0 to 20,000, and the x-axis represents Antibody Concentration ranging from 0.01 to 1000 nM. The graph shows a decrease in CPM with increasing antibody concentration for both samples.](image-url)
B. Anti-CXCL12 Blockade of Binding

CEM Cells

- Anti-CXCL12
- Isotype Control

0.0001 0.001 0.01 0.1 1 10 100

Antibody Concentration (nM)

Figure 2B
Figure 2

C. Calcium flux Ramos

D. Calcium flux CEM

E. Migration Ramos

F. Migration CEM
Figure 3 A

Ramos B Cell Lymphoma Xenograft

- Anti-CXCR4 (MDX-1338)
- Anti-CXCL12
- rituximab
- Isotype Control
- Vehicle (PBS)

Days Post Dosing

Vol ume (LWH/2)
B.

**HL60 Median Tumor Growth**

- MDX-1338 10mg/kg Q3-4Dx5
- Isotype Control 10mg/kg Q3-4Dx5
- Vehicle (PBS) Q3-4Dx5

Days Post Dosing vs. Tumor Volume (LWH/2)
Figure 3C

Median Tumor Growth

Tumor Volume (LWH/2)

Days Post Dosing

- MDX-1338 10 mg/kg Q3-4Dx5
- Isotype Control 10 mg/kg Q3-4Dx5
- MDX-1338 60 mg/kg Q3-4Dx5
- MDX-1338 90 mg/kg Q3-4Dx5
- Vehicle
- cytarabine-C 20 mg/kg
- cytarabine-C 60 mg/kg
- cytarabine-C 90 mg/kg
Figure 3 D

MOLP8
Median Tumor Growth

Tumor Volume (LWH/2)

Days Post Dosing

MDX-1338 10mg/kg
MDX-1338 + bortezomib 0.8mg/kg
MDX-1338 + lenalidomide 50mg/kg
Isotype Control 10mg/kg
Isotype + bortezomib 0.8mg/kg
Isotype + lenalidomide 50 mg/kg
Vehicle
Figure 3 E

JJN3-R
Median Tumor Growth

- MDX-1338 30 mg/kg IP
- MDX-1338 10 mg/kg IP
- Isotype Control 30 mg/kg IP
- bortezomib 0.8 mg/kg IV
- lenalidomide 50 mg/kg IP
- Vehicle 0.3 ml IP

Tumor Volume (LWH/2)

Days Post Dosing
Figure 4 A

Proliferation of Ramos Cells
Abs: 41.25nM
Peptides: 100μM
CPT: 10μM

Untreated = 100%

% Proliferation
Untreated Cells=100%

MDX-138, crosslinked
hlg4 Isotype, crosslinked
Crosslinker only
Anti-CXCL12
mlgG1 Isotype Control
AM13100
BKT140
Camptothecin
Figure 4 B

<table>
<thead>
<tr>
<th>Treatment</th>
<th>FL1-H</th>
<th>FL3-H</th>
</tr>
</thead>
<tbody>
<tr>
<td>No Treatment</td>
<td>1.67</td>
<td>3.19</td>
</tr>
<tr>
<td>Isotype Control</td>
<td>0.51</td>
<td>0.51</td>
</tr>
<tr>
<td>MDX-1338</td>
<td>31.2</td>
<td>5.3</td>
</tr>
<tr>
<td>AMD3100</td>
<td>2.03</td>
<td>2.65</td>
</tr>
</tbody>
</table>

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Figure 4 C

Ramos

Propidium Iodide Percent Positive Cells

0 20 40 60 80

No Treatment  MDX-1338  AMD3100  Isotype Control

Antibody treatment
10 ug/ml for 24 hours
Figure 5 A

A.

R1610-CXCR4 Cells

% Positive Cells

0 10 20 30

No Treatment MDX-1338 Isotype Control

Annexin V

Double Pos
Figure 5 B

R1610 Cells

% Positive Cells

No Treatment  MDX-1338  Isotype Control

0  10  20  30
### Table 1: Apoptosis Data on a Panel of Cell Lines

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>Cell Type</th>
<th>CXCR4 Expression</th>
<th>Adjusted Percent Apoptosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramos*</td>
<td>Lymphoma</td>
<td>++++</td>
<td>71</td>
</tr>
<tr>
<td>Namalwa*</td>
<td>Lymphoma</td>
<td>++++</td>
<td>30</td>
</tr>
<tr>
<td>Raji*</td>
<td>Lymphoma</td>
<td>++++</td>
<td>15</td>
</tr>
<tr>
<td>DHL6*</td>
<td>Lymphoma</td>
<td>+</td>
<td>3</td>
</tr>
<tr>
<td>L540*</td>
<td>Lymphoma</td>
<td>+++</td>
<td>35</td>
</tr>
<tr>
<td>HL60</td>
<td>AML</td>
<td>++</td>
<td>31</td>
</tr>
<tr>
<td>NOMO-1</td>
<td>AML</td>
<td>+++++</td>
<td>34</td>
</tr>
<tr>
<td>KG-1</td>
<td>AML</td>
<td>++</td>
<td>8</td>
</tr>
<tr>
<td>MOLP-8</td>
<td>MM</td>
<td>++</td>
<td>19</td>
</tr>
<tr>
<td>RPMI 8226</td>
<td>MM</td>
<td>++</td>
<td>17</td>
</tr>
<tr>
<td>MM.1S</td>
<td>MM</td>
<td>+</td>
<td>15</td>
</tr>
<tr>
<td>U226</td>
<td>MM</td>
<td>+</td>
<td>22</td>
</tr>
<tr>
<td>JNN3R</td>
<td>MM</td>
<td>++</td>
<td>31</td>
</tr>
<tr>
<td>OPM2</td>
<td>MM</td>
<td>++</td>
<td>17</td>
</tr>
<tr>
<td>L-363</td>
<td>MM</td>
<td>+</td>
<td>16</td>
</tr>
<tr>
<td>MV-4-11</td>
<td>MM</td>
<td>++</td>
<td>1</td>
</tr>
<tr>
<td>MJ</td>
<td>TCL</td>
<td>++</td>
<td>9</td>
</tr>
<tr>
<td>HH</td>
<td>TCL</td>
<td>+++</td>
<td>9</td>
</tr>
<tr>
<td>HuT78</td>
<td>TCL</td>
<td>+</td>
<td>22</td>
</tr>
<tr>
<td>CCRF-CEM*</td>
<td>ALL</td>
<td>+++</td>
<td>45</td>
</tr>
<tr>
<td>NKL</td>
<td>NK</td>
<td>+++</td>
<td>36</td>
</tr>
<tr>
<td>KHYG-1</td>
<td>NK</td>
<td>+</td>
<td>10</td>
</tr>
<tr>
<td>NK-92</td>
<td>NK</td>
<td>++</td>
<td>48</td>
</tr>
<tr>
<td>Human Primary*</td>
<td>B (CD19+)</td>
<td>++</td>
<td>17</td>
</tr>
<tr>
<td>Human Primary*</td>
<td>T (CD3+)</td>
<td>+</td>
<td>6</td>
</tr>
<tr>
<td>Human Primary*</td>
<td>Monocytes (CD14+)</td>
<td>++</td>
<td>24</td>
</tr>
</tbody>
</table>

* Without cross-linker

### CXCR4 Expression Key

<table>
<thead>
<tr>
<th>MFI with 10nM Ab</th>
<th>Score (+)</th>
</tr>
</thead>
<tbody>
<tr>
<td>400-2000</td>
<td>+</td>
</tr>
<tr>
<td>2000-10,000</td>
<td>++</td>
</tr>
<tr>
<td>10,000 - 50,000</td>
<td>+++</td>
</tr>
<tr>
<td>50,000 - 250,000</td>
<td>++++</td>
</tr>
</tbody>
</table>
Clinical Cancer Research


Clin Cancer Res Published OnlineFirst December 4, 2012.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-12-2333

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/early/2012/12/04/1078-0432.CCR-12-2333. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.